Condition
Chronic Hand Eczema (CHE)
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Ruxolitinib
Research Leaders
6 sponsors active, led by IQVIA Inc.
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 3 (1)
Trial Status
Withdrawn1
Enrolling By Invitation1
Clinical Trials (2)
Research Network
Common Treatments
- Ruxolitinib1
- Vehicle1
Active Sponsors
- IQVIA Inc.1
- LEO Pharma1
- Incyte Corporation1
- ICON Clinical Research1
- Optimapharm1
Top Investigators
Incyte Corporation